Moderna D
D
MRNA
246.890
USD
-3.92
(-1.56%)
Pre Open·252.480USD+5.590(+2.26%)
Last updated: · Delayed 15 min
Moderna operating income 2016–2026What are gross, operating and net profit margins? A profit margin is the share of revenue kept as profit: gross margin after the cost of sales, operating margin after running costs, net margin after all costs.
Moderna's operating income in Q3 FY2026, the three months to 30 September 2026, was 130.00M USD, against a loss of 260.00M USD on the same quarter a year before. Moderna's operating income in fiscal year 2025 was -3.07B USD, against a loss of 3.95B USD on the year before.
Last updated 6 Nov 2026 · Next report 12 Feb 2027
Operating income
Operating income Operating margin
Growth
| Fiscal year | Period ending | Operating income | Growth | Operating margin | Gross profit | Gross margin | EBITDA |
|---|---|---|---|---|---|---|---|
| TTM | 30 Sept 2026 | -2.93B | — | -116.04% | 707.00M | 28.00% | -2.56B |
| FY2025 | 31 Dec 2025 | -3.07B | — | -158.13% | 1.08B | 55.35% | -2.55B |
| FY2024 | 31 Dec 2024 | -3.95B | — | -123.32% | 1.74B | 54.24% | -3.39B |
| FY2023 | 31 Dec 2023 | -4.24B | -145.00% | -61.90% | 2.16B | 31.47% | -3.28B |
| FY2022 | 31 Dec 2022 | 9.42B | -29.15% | 49.91% | 13.46B | 71.31% | 9.95B |
| FY2021 | 31 Dec 2021 | 13.30B | — | 74.97% | 15.12B | 85.24% | 13.54B |
| FY2020 | 31 Dec 2020 | -763.14M | — | -94.99% | 764.21M | 95.12% | -703.63M |
| FY2019 | 31 Dec 2019 | -545.72M | — | -906.38% | 29.19M | 48.48% | -477.08M |
| FY2018 | 31 Dec 2018 | -468.87M | — | -347.13% | 110.21M | 81.59% | -412.05M |
| FY2017 | 31 Dec 2017 | -269.36M | — | -130.87% | 185.29M | 90.02% | -235.33M |
| FY2016 | 31 Dec 2016 | -223.77M | — | -206.44% | 93.28M | 86.06% | -208.66M |
| Quarter | Period ending | Operating income | Growth on a year before | Operating margin | Gross profit | Gross margin | EBITDA |
|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 30 Sept 2026 | 130.00M | — | 9.90% | 995.00M | 75.78% | 130.00M |
| Q2 FY2026 | 30 Jun 2026 | -815.00M | — | -562.07% | 52.00M | 35.86% | -704.00M |
| Q1 FY2026 | 31 Mar 2026 | -1.39B | — | -356.81% | -566.00M | -145.50% | -1.26B |
| Q4 FY2025 | 31 Dec 2025 | -857.00M | — | -126.40% | 226.00M | 33.33% | -732.00M |
| Q3 FY2025 | 30 Sept 2025 | -260.00M | — | -25.59% | 8.00M | 0.79% | -135.00M |
| Q2 FY2025 | 30 Jun 2025 | -907.00M | — | -638.73% | 23.00M | 16.20% | -760.00M |
| Q1 FY2025 | 31 Mar 2025 | -1.05B | — | -981.31% | 17.00M | 15.89% | -924.00M |
| Q4 FY2024 | 31 Dec 2024 | -1.25B | -20,866.67% | -130.33% | 217.00M | 22.70% | -1.12B |
| Q3 FY2024 | 30 Sept 2024 | -70.00M | — | -3.77% | 1.34B | 72.29% | 79.00M |
| Q2 FY2024 | 30 Jun 2024 | -1.36B | — | -616.74% | 106.00M | 47.96% | -1.23B |
| Q1 FY2024 | 31 Mar 2024 | -1.27B | — | -758.08% | 71.00M | 42.51% | -1.12B |
| Q4 FY2023 | 31 Dec 2023 | 6.00M | -99.62% | 0.21% | 1.88B | 66.97% | 278.00M |
| Q3 FY2023 | 30 Sept 2023 | -2.01B | -272.56% | -109.89% | -410.00M | -22.39% | -1.70B |
| Q2 FY2023 | 30 Jun 2023 | -1.87B | -176.30% | -542.73% | -387.00M | -112.50% | -1.64B |
| Q1 FY2023 | 31 Mar 2023 | -366.00M | -108.66% | -19.91% | 1.05B | 56.91% | -218.00M |
| Q4 FY2022 | 31 Dec 2022 | 1.58B | -70.79% | 30.69% | 3.23B | 62.75% | 1.75B |
| Q3 FY2022 | 30 Sept 2022 | 1.17B | -67.23% | 36.21% | 2.12B | 65.84% | 1.34B |
| Q2 FY2022 | 30 Jun 2022 | 2.45B | -20.08% | 53.59% | 3.19B | 69.75% | 2.56B |
| Q1 FY2022 | 31 Mar 2022 | 4.23B | +233.89% | 71.16% | 4.92B | 82.88% | 4.31B |
| Q4 FY2021 | 31 Dec 2021 | 5.41B | — | 77.85% | 6.00B | 86.30% | 5.49B |
| Q3 FY2021 | 30 Sept 2021 | 3.56B | — | 73.68% | 4.11B | 85.05% | 3.63B |
| Q2 FY2021 | 30 Jun 2021 | 3.06B | — | 72.65% | 3.47B | 82.21% | 3.14B |
| Q1 FY2021 | 31 Mar 2021 | 1.27B | — | 72.63% | 1.55B | 88.93% | 1.28B |
| Q4 FY2020 | 31 Dec 2020 | -275.04M | — | -48.19% | 555.11M | 97.26% | -259.80M |
| Q3 FY2020 | 30 Sept 2020 | -235.12M | — | -148.89% | 149.41M | 94.62% | -221.44M |
| Q2 FY2020 | 30 Jun 2020 | -122.13M | — | -184.06% | 58.75M | 88.55% | -106.69M |
| Q1 FY2020 | 31 Mar 2020 | -130.86M | — | -1,559.92% | 940.00K | 11.21% | -115.05M |
| Q4 FY2019 | 31 Dec 2019 | -130.56M | — | -928.89% | 5.12M | 36.40% | -113.48M |
| Q3 FY2019 | 30 Sept 2019 | -130.76M | — | -767.12% | 9.75M | 57.17% | -114.53M |
| Q2 FY2019 | 30 Jun 2019 | -143.71M | — | -1,098.44% | 5.58M | 42.67% | -126.34M |
| Q1 FY2019 | 31 Mar 2019 | -141.64M | — | -883.88% | 8.71M | 54.35% | -123.82M |
| Q4 FY2018 | 31 Dec 2018 | -153.03M | — | -432.03% | 28.07M | 79.25% | -132.38M |
| Q3 FY2018 | 30 Sept 2018 | -85.82M | — | -205.52% | 35.28M | 84.48% | -73.85M |
| Q2 FY2018 | 30 Jun 2018 | -97.02M | — | -336.26% | -75.63M | -262.13% | -84.59M |
| Q1 FY2018 | 31 Mar 2018 | -77.40M | — | -266.54% | -61.09M | -210.36% | -67.20M |
| Q4 FY2017 | 31 Dec 2017 | -41.83M | — | -45.51% | 85.99M | 93.56% | -35.91M |
| Q3 FY2017 | 30 Sept 2017 | -67.87M | — | -159.80% | 37.34M | 87.92% | -62.74M |
| Q2 FY2017 | 30 Jun 2017 | -79.83M | — | -223.46% | -63.79M | -178.55% | -75.08M |
| Q1 FY2017 | 31 Mar 2017 | -79.83M | — | -223.46% | -63.79M | -178.55% | -75.08M |
Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.
See also:Revenue,Net income,EPS,Shares outstanding,Cash on hand,Total debt,Free cash flow,Stock buybacks,Income statement
Common questions about Moderna's operating income
Source: Financial Modeling Prep